

Catalog# BP-50551

Relatlimab Biosimilar, Human LAG-3 Monoclonal Antibody

Relatlimab Biosimilar uses the same protein sequences as the therapeutic antibody relatlimab. Relatlimab is a lymphocyte-activation gene 3 (LAG-3)-blocking antibody that is being investigated with other agents in a variety of tumor types. LAG-3 is a cell-surface molecule found on effector T cells and regulatory T cells, and it works to control T cell response, activation, and growth. Preclinical studies suggest that inhibiting LAG-3 could restore effector function of exhausted T cells and could potentially promote an anti-tumor response. LAG-3 is a component of an immune checkpoint pathway that inhibits T-cell activity. Relatlimab, a human IgG4 LAG-3-blocking antibody, restores the effector function of exhausted T cells, reinvigorating T cells to attack cancer.

Relatlimab and the anti-PD-1 agent nivolumab modulate potentially synergistic immune checkpoint pathways and can enhance antitumor immune responses. The two-drug combination has a generally manageable safety profile and can trigger durable tumor regressions in patients with melanoma whose disease has progressed after anti-PD-1 monotherapy.

Product Details	
CAS No.	1673516-98-7
Species Reactivity	Human
Source	Mammalian cells
Isotype	Human IgG4 kappa
Class	Monoclonal
Type	Antibody
Clone	Relatlimab Biosimilar
Conjugate	Unconjugated
Immunogen	Human lymphocyte-activation gene 3 (LAG-3)
Purity	>95%
Molecular Weight	145.58 kDa
Protein Concentration	1 mg/ml
Formulation	0.2 µM filtered solution, pH 5.3
Storage conditions	4°C for short time, -20°C or -80°C for long time.